Literature DB >> 21383724

Recent deal highlights hopes for cancer-killing viruses.

Jon Evans.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21383724     DOI： 10.1038/nm0311-268b

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  10 in total

1.  An intravenous stimulus package for oncolytic virotherapy.

Authors:  Richard Vile; Alan Melcher
Journal:  Mol Ther       Date:  2011-11       Impact factor: 11.454

2.  Complete eradication of xenograft hepatoma by oncolytic adenovirus ZD55 harboring TRAIL-IETD-Smac gene with broad antitumor effect.

Authors:  Shi-Bing Wang; Yuan Tan; Wen Lei; Yi-Gang Wang; Xiu-Mei Zhou; Xiao-Yuan Jia; Kang-Jian Zhang; Liang Chu; Xin-Yuan Liu; Wen-Bin Qian
Journal:  Hum Gene Ther       Date:  2012-07-20       Impact factor: 5.695

Review 3.  Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma.

Authors:  Yi-Gang Wang; Pan-Pan Huang; Rong Zhang; Bu-Yun Ma; Xiu-Mei Zhou; Yan-Fang Sun
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.

Authors:  Robert A Adair; Victoria Roulstone; Karen J Scott; Ruth Morgan; Gerard J Nuovo; Martin Fuller; Deborah Beirne; Emma J West; Victoria A Jennings; Ailsa Rose; Joan Kyula; Sheila Fraser; Rajiv Dave; David A Anthoney; Alison Merrick; Robin Prestwich; Amer Aldouri; Oliver Donnelly; Hardev Pandha; Matt Coffey; Peter Selby; Richard Vile; Giles Toogood; Kevin Harrington; Alan A Melcher
Journal:  Sci Transl Med       Date:  2012-06-13       Impact factor: 17.956

5.  Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion.

Authors:  Moanaro Biswas; John B Johnson; Sandeep R P Kumar; Griffith D Parks; Subbiah Elankumarana; Elankumaran Subbiah
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

6.  Prostate cancer-specific and potent antitumor effect of a DD3-controlled oncolytic virus harboring the PTEN gene.

Authors:  Miao Ding; Xin Cao; Hai-neng Xu; Jun-kai Fan; Hong-ling Huang; Dong-qin Yang; Yu-hua Li; Jian Wang; Runsheng Li; Xin-yuan Liu
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

7.  Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth.

Authors:  Guoqing He; Wen Lei; Shibin Wang; Ruijuan Xiao; Keni Guo; Yulong Xia; Xiumei Zhou; Kangjian Zhang; Xinyuan Liu; Yigang Wang
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-12       Impact factor: 4.322

8.  A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.

Authors:  Yigang Wang; Tao Liu; Panpan Huang; Hongfang Zhao; Rong Zhang; Buyun Ma; Kan Chen; Fang Huang; Xiumei Zhou; Caixia Cui; Xinyuan Liu
Journal:  Oncotarget       Date:  2015-05-30

9.  Potent and specific antitumor effect for colorectal cancer by CEA and Rb double regulated oncolytic adenovirus harboring ST13 gene.

Authors:  Xiumei Zhou; Guoliang Xie; Shibing Wang; Yigang Wang; Kangjian Zhang; Shu Zheng; Liang Chu; Lianli Xiao; Yuemei Yu; Yue Zhang; Xinyuan Liu
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

10.  The Excellent Anti-Tumour Strategy (CTGVT, OV-gene) and the Excellent Anti-Tumor Gene (IL-24).

Authors:  Xin-Yuan Liu
Journal:  Int J Biomed Sci       Date:  2012-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.